🟢 80/100

This product is generally safe

  • Nicotinamide Adenine Dinucleotide: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)
  • 50% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Nicotinamide Adenine Dinucleotide: 125mg is 3.6× the Tolerable Upper Intake Level (35mg)

Label Data

1 Tablet(s) Serving Size
240 Servings
Non-Nutrient/Non-Botanical Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

⚠️ Exceeds Tolerable Upper Intake Level by 3.6× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 125mg UL 35mg
TMG
25 mg
📊 Market median: 496.0mg (192 products) 📚 20 studies — no high-quality reviews
This product: 25mg

Other Ingredients

Mannitol Crospovidone Citrus Burst Monk Fruit extract Magnesium Stearate Silica

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Suggested Use For best results, take one (1) tablet, 2-4 times per day. Place tablet under the tongue to dissolve. May be taken with or without meals.

⚠️ Warnings & Precautions

Pregnant or nursing mothers, children under the age of 18, and individuals with a known medical conditions should consult a physician before using.

Do not use if safety seal is broken or missing.

🧪 Formulation Notes

Supports: Cognition Neurogenesis Memory Metabolism

Nicotinamide Adenine Dinucleotide

No artificial colors, preservatives or additives. Gluten-free. Non-GMO.

Suitable for vegans.

Made in the USA Made in a FDA Registered Facility GMP Good Manufacturing Practice Certified

Additional Information

Store tightly in a cool, dry place.

Made in the USA Made in a FDA Registered Facility GMP Good Manufacturing Practice Certified

Product Details

UPC / SKU 6 56165 99701 5
DSLD Entry Date 2020-07-23
Product Type Non-Nutrient/Non-Botanical
Form Tablet or Pill
DSLD ID 230852
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →